Last edition
News about "IPF"
ArkBio Receives US FDA IND Clearance for AK3280 in Idiopathic Pulmonary Fibrosis
FDA clears ArkBio’s IND application for AK3280, enabling a Phase II proof-of-concept trial in the US to evaluate the novel anti-fibrotic therapy in patients with idiopathic pulmonary fibrosis.
IPF | 12/02/2026 | By News Bureau
Remedy Cell Launches Phase 1b Trial of RC-0315 in IPF
First-in-human study evaluates safety and tolerability of intra-bronchial RC-0315, a cell-derived therapy aimed at reducing fibrosis and restoring lung function in idiopathic pulmonary fibrosis patients.
IPF | 08/01/2026 | By News Bureau | 143
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy